Related Experiment Video
Updated: Jul 13, 2026
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Update on anti-CTLA-4 antibodies in clinical trials
Lee F Langer1, Timothy M Clay, Michael A Morse
1Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Durham, NC 27710, USA.
Abstract:
Breaking immune tolerance against tumor self-antigens is presently an area of intense research in the design of cancer therapies. One possible method to enhance immune system activation against tumor antigens is by blocking the inhibitory co-stimulatory signals mediated by cytotoxic T lymphocyte antigen 4, (CTLA-4) expressed on activated T cells. The fully human monoclonal antibodies that are directed against human CTLA-4, ipilimumab (Medarex/Bristol-Myers Squibb) and CP-675,206 (Pfizer/Abgenix, now Amgen), have demonstrated activity against metastatic melanoma, hormone refractory prostate cancer and other malignancies. They have also uncovered unusual immune-related adverse events manifesting as self-limiting inflammatory reactions of the bowel, skin and pituitary. This article reviews preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events.
Insights
Blocking cytotoxic T lymphocyte antigen 4 (CTLA-4) with monoclonal antibodies like ipilimumab shows promise in cancer therapy by enhancing anti-tumor immunity. This approach can lead to immune-related adverse events, requiring careful monitoring.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Breaking immune tolerance to tumor antigens is crucial for effective cancer therapy.
- Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory co-stimulatory signal on T cells that can be targeted to enhance anti-tumor immune responses.
Purpose of the Study:
- To review the preclinical development and clinical trial data of fully human monoclonal antibodies targeting CTLA-4.
- To assess the efficacy and immune-related adverse events associated with CTLA-4 blockade in cancer patients.
Main Methods:
- Review of preclinical studies involving CTLA-4 blockade.
- Analysis of data from Phase I, II, and III clinical trials of anti-CTLA-4 antibodies (ipilimumab and CP-675,206).
- Evaluation of reported clinical end points and immune-related adverse events.
Main Results:
- Fully human monoclonal antibodies against CTLA-4, such as ipilimumab and CP-675,206, have shown activity in metastatic melanoma, hormone-refractory prostate cancer, and other malignancies.
- These therapies have been associated with unique immune-related adverse events, including inflammatory reactions in the bowel, skin, and pituitary.
Conclusions:
- CTLA-4 blockade represents a promising strategy for enhancing anti-tumor immunity in various cancers.
- Understanding and managing immune-related adverse events is essential for the safe and effective clinical application of CTLA-4 inhibitors.
